PIKFYVE and COVID-19: Though these data suggest PIKfyve inhibitors may not be viable COVID-19 therapeutic, Apilimod remains a strong therapeutic candidate for other diseases, including positive human results against cancers and neurodegenerative disorders14,16,18.